Madrigal Pharmaceuticals (MDGL)

Madrigal’s lead product is Rezdiffra, also known as resmetirom, a once-daily oral therapy designed to activate thyroid hormone receptor beta in the liver. This mechanism is intended to improve liver fat metabolism and address biological drivers of MASH. Rezdiffra became the first FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, marking a major shift for a disease area that had long lacked approved drug therapy.

The company’s business model is now centered on commercial execution, physician education, payer access, and continued clinical development. Madrigal works within a market that involves hepatologists, gastroenterologists, endocrinologists, and primary care physicians, as MASH diagnosis and treatment often require coordination across specialties. Its future performance depends on uptake of Rezdiffra, real-world evidence, competitive developments, reimbursement coverage, and the company’s ability to expand awareness of MASH and appropriate patient identification.